Ono Pharmaceutical (OPHLF) Expected to Announce Earnings on Friday

Ono Pharmaceutical (OTCMKTS:OPHLF) is anticipated to release its resultson Friday, May 8th. Analysts expect Ono Pharmaceutical to post earnings of $0.0520 per share and revenue of $706.7680 million for the quarter.

Ono Pharmaceutical (OTCMKTS:OPHLF) last posted its earnings results on Monday, February 2nd. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.11. The company had revenue of $892.70 million during the quarter, compared to analysts’ expectations of $727.58 million. Ono Pharmaceutical had a net margin of 12.29% and a return on equity of 7.76%. On average, analysts expect Ono Pharmaceutical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Ono Pharmaceutical Price Performance

OTCMKTS OPHLF opened at $14.55 on Wednesday. The firm has a market cap of $6.84 billion, a PE ratio of 16.35 and a beta of 0.33. Ono Pharmaceutical has a one year low of $9.20 and a one year high of $18.67. The stock’s 50 day simple moving average is $14.85 and its 200 day simple moving average is $14.01. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Ono Pharmaceutical to a “hold” rating in a research note on Friday, April 17th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of “Hold”.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.